$15.2 Billion is the total value of Baker Brothers Advisors's 97 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 38.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Seattle Genetics, Inc. | $3,936,672,000 | +16.2% | 51,046,060 | 0.0% | 25.93% | +1.8% | |
| INCY | Buy | Incyte Corporation | $2,366,080,000 | +3.1% | 34,251,309 | +0.0% | 15.59% | -9.6% |
| BGNE | BeiGene, Ltd.sponsored adr | $2,059,721,000 | +12.0% | 11,959,824 | 0.0% | 13.57% | -1.8% | |
| ALXN | Alexion Pharmaceuticals, Inc. | $1,189,355,000 | +12.0% | 8,555,894 | 0.0% | 7.83% | -1.8% | |
| GHDX | Buy | Genomic Health, Inc. | $968,402,000 | +39.3% | 13,790,970 | +0.0% | 6.38% | +22.2% |
| BMRN | BioMarin Pharmaceutical Inc. | $735,332,000 | +2.9% | 7,583,084 | 0.0% | 4.84% | -9.7% | |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $590,396,000 | +42.0% | 28,439,114 | +4.4% | 3.89% | +24.5% |
| AMRN | Buy | Amarin Corporation plcsponsored adr | $554,311,000 | +691.3% | 34,069,509 | +50.3% | 3.65% | +594.1% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $250,377,000 | -23.4% | 1,169,278 | 0.0% | 1.65% | -32.9% | |
| ASND | Ascendis Pharma A/Ssponsored adr | $201,055,000 | +6.5% | 2,837,352 | 0.0% | 1.32% | -6.6% | |
| HRTX | Heron Therapeutics, Inc. | $159,051,000 | -18.5% | 5,025,298 | 0.0% | 1.05% | -28.6% | |
| NVTA | Invitae Corporation | $140,522,000 | +127.6% | 8,399,411 | 0.0% | 0.93% | +99.6% | |
| DBVT | DBV Technologies S.A.sponsored adr | $123,745,000 | +16.4% | 5,509,560 | 0.0% | 0.82% | +2.0% | |
| MRTX | Mirati Therapeutics, Inc. | $118,384,000 | -4.5% | 2,513,462 | 0.0% | 0.78% | -16.2% | |
| NBIX | Neurocrine Biosciences, Inc. | $116,142,000 | +25.2% | 944,624 | 0.0% | 0.76% | +9.8% | |
| BCRX | Buy | BioCryst Pharmaceuticals, Inc. | $115,237,000 | +43.5% | 15,103,081 | +7.8% | 0.76% | +25.9% |
| ARRY | Array BioPharma Inc. | $85,974,000 | -9.4% | 5,656,196 | 0.0% | 0.57% | -20.6% | |
| SAGE | Sell | Sage Therapeutics, Inc. | $80,159,000 | -16.5% | 567,497 | -7.5% | 0.53% | -26.8% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $78,998,000 | -6.7% | 2,708,200 | 0.0% | 0.52% | -18.2% | |
| CERS | Cerus Corporation | $77,507,000 | +8.1% | 10,749,937 | 0.0% | 0.51% | -5.2% | |
| ARGX | Buy | argenx SEsponsored adr | $77,323,000 | -3.0% | 1,019,557 | +6.0% | 0.51% | -15.0% |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $76,500,000 | +47.0% | 3,000,000 | 0.0% | 0.50% | +28.9% | |
| ONCE | Spark Therapeutics, Inc. | $75,504,000 | -34.1% | 1,384,130 | 0.0% | 0.50% | -42.3% | |
| GWPH | Buy | GW Pharmaceuticals plcads | $68,526,000 | +52.6% | 396,700 | +23.3% | 0.45% | +33.8% |
| CBAY | CymaBay Therapeutics, Inc. | $54,488,000 | -17.4% | 4,917,700 | 0.0% | 0.36% | -27.6% | |
| PRNB | New | Principia Biopharma Inc. | $52,240,000 | – | 1,787,807 | +100.0% | 0.34% | – |
| TCDA | Tricida, Inc. | $48,880,000 | +2.2% | 1,600,000 | 0.0% | 0.32% | -10.3% | |
| ECYT | Buy | Endocyte, Inc. | $45,254,000 | +44.0% | 2,548,069 | +11.9% | 0.30% | +26.3% |
| IDRA | Sell | Idera Pharmaceuticals, Inc. | $43,070,000 | -15.6% | 4,833,897 | -87.5% | 0.28% | -25.8% |
| New | Corsicanto II Designated Activity Companynote 3.5% 1/5/2047 | $41,748,000 | – | 10,000,000 | +100.0% | 0.28% | – | |
| INSM | Buy | Insmed Incorporated | $37,447,000 | +126.2% | 1,851,982 | +164.6% | 0.25% | +99.2% |
| AQXP | Aquinox Pharmaceuticals, Inc. | $32,037,000 | +10.6% | 10,934,154 | 0.0% | 0.21% | -3.2% | |
| ABEO | Abeona Therapeutics Inc. | $27,960,000 | -20.0% | 2,184,364 | 0.0% | 0.18% | -30.0% | |
| SLDB | Solid Biosciences Inc. | $27,736,000 | +32.4% | 587,884 | 0.0% | 0.18% | +16.6% | |
| GLPG | Sell | Galapagos NVsponsored adr | $26,667,000 | +11.3% | 237,191 | -8.7% | 0.18% | -2.2% |
| XNCR | Sell | Xencor, Inc. | $23,479,000 | -27.3% | 602,495 | -30.9% | 0.16% | -36.2% |
| MYOK | Sell | MyoKardia, Inc. | $23,290,000 | +8.3% | 357,215 | -17.5% | 0.15% | -5.6% |
| MRUS | Merus N.V. | $22,899,000 | -13.3% | 1,160,014 | 0.0% | 0.15% | -23.7% | |
| QURE | uniQure N.V. | $22,016,000 | -3.7% | 605,000 | 0.0% | 0.14% | -15.7% | |
| SGMO | Sangamo Therapeutics, Inc. | $21,762,000 | +19.4% | 1,283,923 | 0.0% | 0.14% | +4.4% | |
| CMTA | Buy | Clementia Pharmaceuticals Inc. | $21,560,000 | +37.4% | 1,933,624 | +62.1% | 0.14% | +20.3% |
| ZYME | Zymeworks Inc. | $20,584,000 | +6.2% | 1,311,085 | 0.0% | 0.14% | -6.8% | |
| AIMT | Aimmune Therapeutics, Inc. | $18,384,000 | +1.5% | 673,908 | 0.0% | 0.12% | -11.0% | |
| New | Neurocrine Biosciences, Inc.note 2.25% 5/15/2024 | $17,062,000 | – | 10,000,000 | +100.0% | 0.11% | – | |
| BLCM | Sell | Bellicum Pharmaceuticals, Inc. | $16,495,000 | -45.4% | 2,677,818 | -34.6% | 0.11% | -52.0% |
| New | BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $15,818,000 | – | 15,000,000 | +100.0% | 0.10% | – | |
| BOLD | Audentes Therapeutics, Inc. | $15,568,000 | +3.6% | 393,222 | 0.0% | 0.10% | -8.8% | |
| CFRX | ContraFect Corporation | $14,807,000 | -6.3% | 7,153,076 | 0.0% | 0.10% | -17.6% | |
| AGLE | Aeglea BioTherapeutics, Inc. | $13,282,000 | -9.5% | 1,387,872 | 0.0% | 0.09% | -20.9% | |
| New | BioMarin Pharmaceutical Inc.note 0.75% 10/15/2018 | $12,599,000 | – | 12,228,000 | +100.0% | 0.08% | – | |
| ANAB | Buy | AnaptysBio, Inc. | $11,283,000 | +117.3% | 113,086 | +54.7% | 0.07% | +89.7% |
| CPRX | Sell | Catalyst Pharmaceuticals, Inc. | $10,962,000 | -3.0% | 2,900,000 | -19.9% | 0.07% | -15.3% |
| ERYP | Sell | ERYTECH Pharma S.A.sponsored adr | $9,307,000 | -73.0% | 1,085,969 | -64.8% | 0.06% | -76.4% |
| NVAX | New | Novavax, Inc. | $8,870,000 | – | 4,718,318 | +100.0% | 0.06% | – |
| BLUE | Sell | bluebird bio, Inc. | $8,678,000 | -72.4% | 59,441 | -70.3% | 0.06% | -75.8% |
| HALO | Sell | Halozyme Therapeutics, Inc. | $8,176,000 | -62.3% | 449,969 | -65.0% | 0.05% | -66.9% |
| ALBO | Albireo Pharma, Inc. | $8,240,000 | -7.2% | 250,000 | 0.0% | 0.05% | -19.4% | |
| MNTA | Momenta Pharmaceuticals, Inc. | $8,114,000 | +28.6% | 308,500 | 0.0% | 0.05% | +12.8% | |
| SBPH | Buy | Spring Bank Pharmaceuticals, Inc. | $7,388,000 | +67.1% | 613,144 | +64.3% | 0.05% | +48.5% |
| VKTX | New | Viking Therapeutics, Inc. | $7,404,000 | – | 425,000 | +100.0% | 0.05% | – |
| AUTL | Autolus Therapeutics plcspon ads | $7,216,000 | +14.5% | 235,294 | 0.0% | 0.05% | +2.1% | |
| SYRS | Syros Pharmaceuticals, Inc. | $6,846,000 | +16.6% | 574,835 | 0.0% | 0.04% | +2.3% | |
| MNLO | Menlo Therapeutics Inc. | $6,895,000 | +21.3% | 700,000 | 0.0% | 0.04% | +4.7% | |
| GTHX | Sell | G1 Therapeutics, Inc. | $6,653,000 | -9.7% | 127,236 | -24.9% | 0.04% | -20.0% |
| IFRX | Sell | InflaRx N.V. | $6,143,000 | -26.4% | 178,987 | -30.8% | 0.04% | -36.5% |
| ACHN | Sell | Achillion Pharmaceuticals, Inc. | $6,035,000 | +9.7% | 1,639,948 | -15.6% | 0.04% | -2.4% |
| ARWR | New | Arrowhead Pharmaceuticals, Inc. | $5,895,000 | – | 307,496 | +100.0% | 0.04% | – |
| ASMB | Assembly Biosciences, Inc. | $5,519,000 | -5.3% | 148,587 | 0.0% | 0.04% | -18.2% | |
| NTLA | Sell | Intellia Therapeutics, Inc. | $5,510,000 | -63.2% | 192,538 | -64.8% | 0.04% | -67.9% |
| CCXI | ChemoCentryx, Inc. | $5,233,000 | -4.0% | 414,029 | 0.0% | 0.03% | -17.1% | |
| GNMX | Sell | Aevi Genomic Medicine, Inc. | $4,859,000 | +8.0% | 3,950,419 | -2.6% | 0.03% | -5.9% |
| XLRN | Sell | Acceleron Pharma Inc. | $4,802,000 | -39.6% | 83,900 | -48.8% | 0.03% | -46.7% |
| GLMD | Sell | Galmed Pharmaceuticals Ltd. | $4,401,000 | -41.9% | 324,094 | -49.1% | 0.03% | -49.1% |
| ALKS | Alkermes plc | $4,255,000 | +3.1% | 100,251 | 0.0% | 0.03% | -9.7% | |
| FOMX | Sell | Foamix Pharmaceuticals Ltd. | $3,943,000 | -47.2% | 688,075 | -53.8% | 0.03% | -53.6% |
| YMAB | New | Y-mAbs Therapeutics, Inc. | $3,984,000 | – | 150,000 | +100.0% | 0.03% | – |
| FTSV | Forty Seven, Inc. | $3,730,000 | -6.8% | 250,000 | 0.0% | 0.02% | -16.7% | |
| CRNX | New | Crinetics Pharmaceuticals, Inc. | $3,760,000 | – | 131,250 | +100.0% | 0.02% | – |
| APLS | Apellis Pharmaceuticals, Inc. | $3,486,000 | -19.2% | 196,078 | 0.0% | 0.02% | -28.1% | |
| ADMS | Adamas Pharmaceuticals, Inc. | $3,456,000 | -22.5% | 172,630 | 0.0% | 0.02% | -32.4% | |
| VSAR | Versartis, Inc. | $3,397,000 | -30.9% | 2,426,310 | 0.0% | 0.02% | -40.5% | |
| RARX | Ra Pharmaceuticals, Inc. | $3,219,000 | +81.8% | 177,952 | 0.0% | 0.02% | +61.5% | |
| LJPC | La Jolla Pharmaceutical Company | $3,114,000 | -31.0% | 154,675 | 0.0% | 0.02% | -38.2% | |
| Sell | Trillium Therapeutics Inc. | $2,931,000 | -4.6% | 505,262 | -1.3% | 0.02% | -17.4% | |
| KRYS | Sell | Krystal Biotech, Inc. | $2,016,000 | -32.2% | 114,674 | -42.7% | 0.01% | -40.9% |
| RCUS | Arcus Biosciences, Inc. | $1,694,000 | +13.8% | 121,534 | 0.0% | 0.01% | 0.0% | |
| AQST | New | Aquestive Therapeutics, Inc. | $1,744,000 | – | 99,600 | +100.0% | 0.01% | – |
| INFI | Infinity Pharmaceuticals, Inc. | $1,573,000 | +41.8% | 580,400 | 0.0% | 0.01% | +25.0% | |
| MTEM | Buy | Molecular Templates, Inc. | $1,370,000 | +261.5% | 254,230 | +251.1% | 0.01% | +200.0% |
| OVID | Sell | Ovid Therapeutics Inc. | $1,260,000 | -34.8% | 222,139 | -10.3% | 0.01% | -46.7% |
| SNSS | Sunesis Pharmaceuticals, Inc. | $1,113,000 | -5.7% | 556,665 | 0.0% | 0.01% | -22.2% | |
| DVAX | Dynavax Technologies Corporation | $930,000 | -18.7% | 75,000 | 0.0% | 0.01% | -33.3% | |
| CNST | New | Constellation Pharmaceuticals, Inc. | $897,000 | – | 133,333 | +100.0% | 0.01% | – |
| AFMD | Sell | Affimed N.V. | $870,000 | +31.8% | 200,000 | -50.0% | 0.01% | +20.0% |
| PRTO | Proteon Therapeutics, Inc. | $582,000 | -20.5% | 298,591 | 0.0% | 0.00% | -33.3% | |
| FLGT | Fulgent Genetics, Inc. | $491,000 | -5.2% | 125,000 | 0.0% | 0.00% | -25.0% | |
| RTTR | Ritter Pharmaceuticals, Inc. | $521,000 | -27.6% | 279,999 | 0.0% | 0.00% | -40.0% | |
| BTXWS | Exit | BioTime, Inc.*w exp 10/1/201 | $0 | – | -20,084 | -100.0% | 0.00% | – |
| AKTX | Exit | Akari Therapeutics, Plcsponsored adr | $0 | – | -58,770 | -100.0% | -0.00% | – |
| CYCCP | Exit | Cyclacel Pharmaceuticals, Inc.pfd conv ex 6% | $0 | – | -13,253 | -100.0% | -0.00% | – |
| STML | Exit | Stemline Therapeutics, Inc. | $0 | – | -44,524 | -100.0% | -0.01% | – |
| BDSI | Exit | BioDelivery Sciences International, Inc. | $0 | – | -210,021 | -100.0% | -0.01% | – |
| TTOO | Exit | T2 Biosystems, Inc. | $0 | – | -100,000 | -100.0% | -0.01% | – |
| JNCE | Exit | Jounce Therapeutics, Inc. | $0 | – | -100,000 | -100.0% | -0.01% | – |
| CRBP | Exit | Corbus Pharmaceuticals Holdings, Inc. | $0 | – | -247,450 | -100.0% | -0.01% | – |
| SELB | Exit | Selecta Biosciences, Inc. | $0 | – | -93,750 | -100.0% | -0.01% | – |
| ADAP | Exit | Adaptimmune Therapeutics plcsponsored adr | $0 | – | -100,000 | -100.0% | -0.01% | – |
| ABUS | Exit | Arbutus Biopharma Corporation | $0 | – | -180,582 | -100.0% | -0.01% | – |
| TRVN | Exit | Trevena, Inc. | $0 | – | -950,000 | -100.0% | -0.01% | – |
| CLLS | Exit | Cellectis S.A.sponsored ads | $0 | – | -50,000 | -100.0% | -0.01% | – |
| MDWD | Exit | MediWound Ltd. | $0 | – | -226,000 | -100.0% | -0.01% | – |
| NLNK | Exit | NewLink Genetics Corporation | $0 | – | -507,273 | -100.0% | -0.02% | – |
| RIGL | Exit | Rigel Pharmaceuticals, Inc. | $0 | – | -1,041,612 | -100.0% | -0.02% | – |
| TNXP | Exit | Tonix Pharmaceuticals Holdings Corp. | $0 | – | -699,500 | -100.0% | -0.02% | – |
| TTPH | Exit | Tetraphase Pharmaceuticals, Inc. | $0 | – | -935,000 | -100.0% | -0.02% | – |
| Exit | Nabriva Therapeutics plc | $0 | – | -938,235 | -100.0% | -0.02% | – | |
| AERI | Exit | Aerie Pharmaceuticals, Inc. | $0 | – | -60,155 | -100.0% | -0.03% | – |
| NTRA | Exit | Natera, Inc. | $0 | – | -228,676 | -100.0% | -0.03% | – |
| MGNX | Exit | MacroGenics, Inc. | $0 | – | -217,695 | -100.0% | -0.03% | – |
| GLYC | Exit | GlycoMimetics, Inc. | $0 | – | -291,214 | -100.0% | -0.04% | – |
| ACOR | Exit | Acorda Therapeutics, Inc. | $0 | – | -173,100 | -100.0% | -0.04% | – |
| SESN | Exit | Sesen Bio, Inc. | $0 | – | -2,624,412 | -100.0% | -0.04% | – |
| VNDA | Exit | Vanda Pharmaceuticals Inc. | $0 | – | -310,354 | -100.0% | -0.04% | – |
| Exit | Aegerion Pharmaceuticals, Inc.note 2% 8/15/2019 | $0 | – | -9,517,000 | -100.0% | -0.04% | – | |
| PGNX | Exit | Progenics Pharmaceuticals, Inc. | $0 | – | -979,016 | -100.0% | -0.06% | – |
| Exit | Corsicanto II Designated Activity Companynote 3.5% 1/5/2047 | $0 | – | -10,000,000 | -100.0% | -0.08% | – | |
| EXEL | Exit | Exelixis, Inc. | $0 | – | -513,410 | -100.0% | -0.08% | – |
| Exit | BioMarin Pharmaceutical Inc.note 0.75% 10/15/2018 | $0 | – | -12,228,000 | -100.0% | -0.10% | – | |
| Exit | Neurocrine Biosciences, Inc.note 2.25% 5/15/2024 | $0 | – | -10,000,000 | -100.0% | -0.11% | – | |
| Exit | BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $0 | – | -15,000,000 | -100.0% | -0.11% | – | |
| Exit | Novavax, Inc.note 3.75% 2/1/23 | $0 | – | -73,500,000 | -100.0% | -0.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.